Animalcare Group Plc (ANCR) - Total Assets
Based on the latest financial reports, Animalcare Group Plc (ANCR) holds total assets worth GBX163.87 Million GBX (≈ $19.94K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Animalcare Group Plc net assets for net asset value and shareholders' equity analysis.
Animalcare Group Plc - Total Assets Trend (2000–2024)
This chart illustrates how Animalcare Group Plc's total assets have evolved over time, based on quarterly financial data.
Animalcare Group Plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Animalcare Group Plc's total assets of GBX163.87 Million consist of 61.7% current assets and 38.3% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 7.4% |
| Accounts Receivable | GBX14.20 Million | 8.9% |
| Inventory | GBX11.75 Million | 7.4% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX16.60 Million | 10.5% |
| Goodwill | GBX39.36 Million | 24.8% |
Asset Composition Trend (2000–2024)
This chart illustrates how Animalcare Group Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ANCR market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Animalcare Group Plc's current assets represent 61.7% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 7.4% of total assets in 2024, down from 12.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 24.8% of total assets.
Animalcare Group Plc Competitors by Total Assets
Key competitors of Animalcare Group Plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Animalcare Group Plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 3.27 | 1.77 |
| Quick Ratio | 1.27 | 2.67 | 0.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX20.03 Million | GBX42.65 Million | GBX13.08 Million |
Animalcare Group Plc - Advanced Valuation Insights
This section examines the relationship between Animalcare Group Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.72 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 48.7% |
| Total Assets | GBX158.81 Million |
| Market Capitalization | $2.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Animalcare Group Plc's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Animalcare Group Plc's assets grew by 48.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Animalcare Group Plc (2000–2024)
The table below shows the annual total assets of Animalcare Group Plc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | GBX158.81 Million ≈ $19.32K |
+48.71% |
| 2023-12-31 | GBX106.79 Million ≈ $12.99K |
-9.68% |
| 2022-12-31 | GBX118.24 Million ≈ $14.39K |
+7.49% |
| 2021-12-31 | GBX110.00 Million ≈ $13.38K |
-11.60% |
| 2020-12-31 | GBX124.44 Million ≈ $15.14K |
-2.97% |
| 2019-12-31 | GBX128.24 Million ≈ $15.60K |
-10.66% |
| 2018-12-31 | GBX143.55 Million ≈ $17.47K |
-5.19% |
| 2017-12-31 | GBX151.40 Million ≈ $18.42K |
+426.52% |
| 2017-06-30 | GBX28.75 Million ≈ $3.50K |
+7.01% |
| 2016-06-30 | GBX26.87 Million ≈ $3.27K |
+9.79% |
| 2015-06-30 | GBX24.47 Million ≈ $2.98K |
+8.65% |
| 2014-06-30 | GBX22.52 Million ≈ $2.74K |
+4.84% |
| 2013-06-30 | GBX21.49 Million ≈ $2.61K |
+9.94% |
| 2012-06-30 | GBX19.54 Million ≈ $2.38K |
+4.05% |
| 2011-06-30 | GBX18.78 Million ≈ $2.29K |
-18.62% |
| 2010-06-30 | GBX23.08 Million ≈ $2.81K |
-8.99% |
| 2009-06-30 | GBX25.36 Million ≈ $3.09K |
+1.73% |
| 2008-06-30 | GBX24.93 Million ≈ $3.03K |
+230.56% |
| 2007-06-30 | GBX7.54 Million ≈ $917.64 |
-3.13% |
| 2006-06-30 | GBX7.79 Million ≈ $947.33 |
+15.66% |
| 2005-06-30 | GBX6.73 Million ≈ $819.09 |
+13.70% |
| 2004-06-30 | GBX5.92 Million ≈ $720.41 |
+2.90% |
| 2003-06-30 | GBX5.75 Million ≈ $700.10 |
-3.68% |
| 2002-06-30 | GBX5.97 Million ≈ $726.86 |
+64.98% |
| 2001-06-30 | GBX3.62 Million ≈ $440.57 |
+25.95% |
| 2000-06-30 | GBX2.88 Million ≈ $349.80 |
-- |
About Animalcare Group Plc
Animalcare Group plc develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets. The company has a collaboration with 272Bio Limited to develop and commercialize a novel biological treatment for a common equine skin condition, known as sweet itch. The company operates in Belgium, the Netherlands, the Unite… Read more